GlassScriptPhysician profile
Neeraj Jain
NPI 1144425539
$1,160.15
in general payments reported to CMS, 2019-2025
17 companies · $13.58 in 2025
The $13.58 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2022: $203 · 2023: $408 · 2024: $296 · 2025: $13.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697 · Education: $20.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.71 |
| Education | $20.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.81 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $156.10 | 2024-2025 | |
| Insmed, INC. | $106.21 | 2019 | |
| Travere Therapeutics, INC. | $100.25 | 2022-2024 | |
| Amgen INC. | $90.10 | 2022-2024 | Tavneos |
| Calliditas Therapeutics US INC. | $76.87 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $70.71 | 2022-2023 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $70.54 | 2022-2023 | |
| Glaxosmithkline, LLC. | $43.94 | 2023-2024 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $41.81 | 2023 | Jynarque |
| Ani Pharmaceuticals, INC. | $36.47 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2023 | Gattex |
| Eisai INC. | $24.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $20.56 | 2023 | Rayaldee |
| Genzyme Corporation | $18.88 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $17.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.52 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.